nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.0379	0.0474	CbGbCtD
Propranolol—SLC22A2—Zidovudine—acquired immunodeficiency syndrome	0.0301	0.0376	CbGbCtD
Propranolol—SLC22A2—Lamivudine—acquired immunodeficiency syndrome	0.0233	0.0291	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0226	0.0282	CbGbCtD
Propranolol—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0226	0.0282	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.0195	0.0243	CbGbCtD
Propranolol—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.0195	0.0243	CbGbCtD
Propranolol—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0189	0.0236	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0189	0.0236	CbGbCtD
Propranolol—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0187	0.0234	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0171	0.0214	CbGbCtD
Propranolol—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0171	0.0214	CbGbCtD
Propranolol—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0171	0.0214	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0171	0.0214	CbGbCtD
Propranolol—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0169	0.0212	CbGbCtD
Propranolol—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0169	0.0212	CbGbCtD
Propranolol—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0161	0.0201	CbGbCtD
Propranolol—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0151	0.0189	CbGbCtD
Propranolol—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0148	0.0185	CbGbCtD
Propranolol—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0146	0.0183	CbGbCtD
Propranolol—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0142	0.0177	CbGbCtD
Propranolol—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0139	0.0174	CbGbCtD
Propranolol—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0139	0.0174	CbGbCtD
Propranolol—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0137	0.0171	CbGbCtD
Propranolol—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0137	0.0171	CbGbCtD
Propranolol—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0128	0.016	CbGbCtD
Propranolol—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0128	0.016	CbGbCtD
Propranolol—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0126	0.0157	CbGbCtD
Propranolol—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0122	0.0153	CbGbCtD
Propranolol—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0122	0.0152	CbGbCtD
Propranolol—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0118	0.0147	CbGbCtD
Propranolol—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0115	0.0143	CbGbCtD
Propranolol—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0115	0.0143	CbGbCtD
Propranolol—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0114	0.0143	CbGbCtD
Propranolol—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.011	0.0138	CbGbCtD
Propranolol—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0106	0.0132	CbGbCtD
Propranolol—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0104	0.013	CbGbCtD
Propranolol—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0104	0.013	CbGbCtD
Propranolol—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0103	0.0129	CbGbCtD
Propranolol—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0103	0.0129	CbGbCtD
Propranolol—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.00992	0.0124	CbGbCtD
Propranolol—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00955	0.0119	CbGbCtD
Propranolol—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00951	0.0119	CbGbCtD
Propranolol—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00923	0.0115	CbGbCtD
Propranolol—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00896	0.0112	CbGbCtD
Propranolol—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0087	0.0109	CbGbCtD
Propranolol—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00835	0.0104	CbGbCtD
Propranolol—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00835	0.0104	CbGbCtD
Propranolol—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.008	0.01	CbGbCtD
Propranolol—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00787	0.00983	CbGbCtD
Propranolol—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00787	0.00983	CbGbCtD
Propranolol—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00776	0.0097	CbGbCtD
Propranolol—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0073	0.00912	CbGbCtD
Propranolol—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0073	0.00912	CbGbCtD
Propranolol—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0066	0.00825	CbGbCtD
Propranolol—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0066	0.00825	CbGbCtD
Propranolol—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00619	0.00774	CbGbCtD
Propranolol—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0057	0.00712	CbGbCtD
Propranolol—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00553	0.00691	CbGbCtD
Propranolol—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.005	0.00625	CbGbCtD
Propranolol—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.005	0.00625	CbGbCtD
Propranolol—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0048	0.00599	CbGbCtD
Propranolol—ORM1—saliva—acquired immunodeficiency syndrome	0.00342	0.128	CbGeAlD
Propranolol—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00113	0.0422	CbGeAlD
Propranolol—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00105	0.0394	CbGeAlD
Propranolol—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000859	0.0322	CbGeAlD
Propranolol—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000829	0.031	CbGeAlD
Propranolol—SLC22A2—digestive system—acquired immunodeficiency syndrome	0.000743	0.0278	CbGeAlD
Propranolol—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000622	0.0233	CbGeAlD
Propranolol—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000612	0.0229	CbGeAlD
Propranolol—ORM1—blood—acquired immunodeficiency syndrome	0.000546	0.0204	CbGeAlD
Propranolol—ORM1—bone marrow—acquired immunodeficiency syndrome	0.000528	0.0198	CbGeAlD
Propranolol—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000526	0.0197	CbGeAlD
Propranolol—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.000493	0.0185	CbGeAlD
Propranolol—ORM1—lung—acquired immunodeficiency syndrome	0.000479	0.0179	CbGeAlD
Propranolol—ORM1—nervous system—acquired immunodeficiency syndrome	0.000443	0.0166	CbGeAlD
Propranolol—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00044	0.0165	CbGeAlD
Propranolol—ORM1—central nervous system—acquired immunodeficiency syndrome	0.000427	0.016	CbGeAlD
Propranolol—ADRB1—lung—acquired immunodeficiency syndrome	0.000422	0.0158	CbGeAlD
Propranolol—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000416	0.0156	CbGeAlD
Propranolol—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000408	0.0153	CbGeAlD
Propranolol—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000405	0.0151	CbGeAlD
Propranolol—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.0004	0.015	CbGeAlD
Propranolol—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000398	0.0149	CbGeAlD
Propranolol—ADRB1—nervous system—acquired immunodeficiency syndrome	0.000391	0.0146	CbGeAlD
Propranolol—CYP2C19—blood—acquired immunodeficiency syndrome	0.000385	0.0144	CbGeAlD
Propranolol—ADRB1—central nervous system—acquired immunodeficiency syndrome	0.000376	0.0141	CbGeAlD
Propranolol—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000357	0.0134	CbGeAlD
Propranolol—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000335	0.0126	CbGeAlD
Propranolol—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.00033	0.0124	CbGeAlD
Propranolol—ORM1—lymph node—acquired immunodeficiency syndrome	0.000327	0.0123	CbGeAlD
Propranolol—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.000326	0.0122	CbGeAlD
Propranolol—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000323	0.0121	CbGeAlD
Propranolol—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000319	0.0119	CbGeAlD
Propranolol—HTR1B—brain—acquired immunodeficiency syndrome	0.000318	0.0119	CbGeAlD
Propranolol—CYP1A2—blood—acquired immunodeficiency syndrome	0.000315	0.0118	CbGeAlD
Propranolol—CYP1A1—blood—acquired immunodeficiency syndrome	0.000311	0.0116	CbGeAlD
Propranolol—CYP3A5—blood—acquired immunodeficiency syndrome	0.000304	0.0114	CbGeAlD
Propranolol—ADRB1—brain—acquired immunodeficiency syndrome	0.000299	0.0112	CbGeAlD
Propranolol—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000288	0.0108	CbGeAlD
Propranolol—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000281	0.0105	CbGeAlD
Propranolol—CYP1A2—lung—acquired immunodeficiency syndrome	0.000276	0.0103	CbGeAlD
Propranolol—CYP1A1—lung—acquired immunodeficiency syndrome	0.000272	0.0102	CbGeAlD
Propranolol—CYP3A5—lung—acquired immunodeficiency syndrome	0.000266	0.00997	CbGeAlD
Propranolol—HTR1A—brain—acquired immunodeficiency syndrome	0.000256	0.00959	CbGeAlD
Propranolol—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.000252	0.00944	CbGeAlD
Propranolol—Erythema multiforme—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.00145	CcSEcCtD
Propranolol—Agitation—Delavirdine—acquired immunodeficiency syndrome	0.000251	0.00145	CcSEcCtD
Propranolol—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000251	0.00145	CcSEcCtD
Propranolol—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00025	0.00144	CcSEcCtD
Propranolol—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000249	0.00144	CcSEcCtD
Propranolol—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000249	0.00144	CcSEcCtD
Propranolol—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000249	0.00144	CcSEcCtD
Propranolol—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000249	0.00144	CcSEcCtD
Propranolol—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.000247	0.00143	CcSEcCtD
Propranolol—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.000246	0.00142	CcSEcCtD
Propranolol—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.000246	0.00142	CcSEcCtD
Propranolol—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000245	0.00142	CcSEcCtD
Propranolol—Vertigo—Delavirdine—acquired immunodeficiency syndrome	0.000245	0.00142	CcSEcCtD
Propranolol—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000245	0.00141	CcSEcCtD
Propranolol—Mental disorder—Saquinavir—acquired immunodeficiency syndrome	0.000244	0.00141	CcSEcCtD
Propranolol—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000243	0.00909	CbGeAlD
Propranolol—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.000243	0.0014	CcSEcCtD
Propranolol—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000243	0.0014	CcSEcCtD
Propranolol—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000243	0.0014	CcSEcCtD
Propranolol—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000242	0.0014	CcSEcCtD
Propranolol—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000242	0.0014	CcSEcCtD
Propranolol—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000241	0.0014	CcSEcCtD
Propranolol—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000241	0.0014	CcSEcCtD
Propranolol—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000241	0.0014	CcSEcCtD
Propranolol—ABCB1—retina—acquired immunodeficiency syndrome	0.000241	0.00903	CbGeAlD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000241	0.00139	CcSEcCtD
Propranolol—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000241	0.00139	CcSEcCtD
Propranolol—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000241	0.00139	CcSEcCtD
Propranolol—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00024	0.00139	CcSEcCtD
Propranolol—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000239	0.00138	CcSEcCtD
Propranolol—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000239	0.00896	CbGeAlD
Propranolol—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000239	0.00138	CcSEcCtD
Propranolol—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000238	0.00138	CcSEcCtD
Propranolol—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000238	0.00138	CcSEcCtD
Propranolol—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.000238	0.00137	CcSEcCtD
Propranolol—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000237	0.00137	CcSEcCtD
Propranolol—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000237	0.00137	CcSEcCtD
Propranolol—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000236	0.00136	CcSEcCtD
Propranolol—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000235	0.00881	CbGeAlD
Propranolol—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000235	0.00136	CcSEcCtD
Propranolol—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000235	0.00136	CcSEcCtD
Propranolol—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000233	0.00135	CcSEcCtD
Propranolol—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000232	0.00134	CcSEcCtD
Propranolol—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.000232	0.00134	CcSEcCtD
Propranolol—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.000231	0.00134	CcSEcCtD
Propranolol—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.00023	0.00133	CcSEcCtD
Propranolol—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000229	0.00132	CcSEcCtD
Propranolol—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000228	0.00132	CcSEcCtD
Propranolol—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000228	0.00132	CcSEcCtD
Propranolol—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000228	0.00132	CcSEcCtD
Propranolol—CYP3A4—blood—acquired immunodeficiency syndrome	0.000228	0.00853	CbGeAlD
Propranolol—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000226	0.00131	CcSEcCtD
Propranolol—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000226	0.00131	CcSEcCtD
Propranolol—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000226	0.00131	CcSEcCtD
Propranolol—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000226	0.00131	CcSEcCtD
Propranolol—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000226	0.00131	CcSEcCtD
Propranolol—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000225	0.0013	CcSEcCtD
Propranolol—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000224	0.0013	CcSEcCtD
Propranolol—CYP2D6—blood—acquired immunodeficiency syndrome	0.000224	0.0084	CbGeAlD
Propranolol—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000223	0.00129	CcSEcCtD
Propranolol—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000223	0.00129	CcSEcCtD
Propranolol—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000223	0.00129	CcSEcCtD
Propranolol—Rash—Didanosine—acquired immunodeficiency syndrome	0.000221	0.00128	CcSEcCtD
Propranolol—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000221	0.00128	CcSEcCtD
Propranolol—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000221	0.00128	CcSEcCtD
Propranolol—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000221	0.00128	CcSEcCtD
Propranolol—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000221	0.00128	CcSEcCtD
Propranolol—Cough—Ritonavir—acquired immunodeficiency syndrome	0.00022	0.00127	CcSEcCtD
Propranolol—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000219	0.00127	CcSEcCtD
Propranolol—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000219	0.00127	CcSEcCtD
Propranolol—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000219	0.00127	CcSEcCtD
Propranolol—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000218	0.00126	CcSEcCtD
Propranolol—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000218	0.00126	CcSEcCtD
Propranolol—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000218	0.00126	CcSEcCtD
Propranolol—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000217	0.00125	CcSEcCtD
Propranolol—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000216	0.00125	CcSEcCtD
Propranolol—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000216	0.00125	CcSEcCtD
Propranolol—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000216	0.00125	CcSEcCtD
Propranolol—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000215	0.00124	CcSEcCtD
Propranolol—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000214	0.00124	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000213	0.00123	CcSEcCtD
Propranolol—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000212	0.00123	CcSEcCtD
Propranolol—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000212	0.00123	CcSEcCtD
Propranolol—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000212	0.00122	CcSEcCtD
Propranolol—Pain—Indinavir—acquired immunodeficiency syndrome	0.00021	0.00122	CcSEcCtD
Propranolol—Constipation—Indinavir—acquired immunodeficiency syndrome	0.00021	0.00122	CcSEcCtD
Propranolol—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.00021	0.00122	CcSEcCtD
Propranolol—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00021	0.00122	CcSEcCtD
Propranolol—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.00021	0.00122	CcSEcCtD
Propranolol—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000209	0.00121	CcSEcCtD
Propranolol—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000209	0.00121	CcSEcCtD
Propranolol—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000209	0.00121	CcSEcCtD
Propranolol—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000209	0.00121	CcSEcCtD
Propranolol—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000208	0.0012	CcSEcCtD
Propranolol—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000208	0.0012	CcSEcCtD
Propranolol—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000208	0.0012	CcSEcCtD
Propranolol—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000207	0.0012	CcSEcCtD
Propranolol—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000207	0.0012	CcSEcCtD
Propranolol—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000205	0.00119	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000205	0.00119	CcSEcCtD
Propranolol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000205	0.00118	CcSEcCtD
Propranolol—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000202	0.00117	CcSEcCtD
Propranolol—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000202	0.00117	CcSEcCtD
Propranolol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000202	0.00117	CcSEcCtD
Propranolol—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000202	0.00117	CcSEcCtD
Propranolol—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000201	0.00116	CcSEcCtD
Propranolol—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000201	0.00116	CcSEcCtD
Propranolol—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000201	0.00116	CcSEcCtD
Propranolol—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000201	0.00116	CcSEcCtD
Propranolol—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000201	0.00116	CcSEcCtD
Propranolol—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.0002	0.00116	CcSEcCtD
Propranolol—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.0002	0.00116	CcSEcCtD
Propranolol—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.00116	CcSEcCtD
Propranolol—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.0002	0.00116	CcSEcCtD
Propranolol—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000199	0.00115	CcSEcCtD
Propranolol—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000199	0.00115	CcSEcCtD
Propranolol—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000199	0.00115	CcSEcCtD
Propranolol—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000199	0.00115	CcSEcCtD
Propranolol—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000198	0.00115	CcSEcCtD
Propranolol—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000198	0.00115	CcSEcCtD
Propranolol—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000198	0.00114	CcSEcCtD
Propranolol—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000197	0.00114	CcSEcCtD
Propranolol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000196	0.00113	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000196	0.00113	CcSEcCtD
Propranolol—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000196	0.00113	CcSEcCtD
Propranolol—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000195	0.00112	CcSEcCtD
Propranolol—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000195	0.00112	CcSEcCtD
Propranolol—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000194	0.00112	CcSEcCtD
Propranolol—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000194	0.00112	CcSEcCtD
Propranolol—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000194	0.00112	CcSEcCtD
Propranolol—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000193	0.00112	CcSEcCtD
Propranolol—CYP1A1—brain—acquired immunodeficiency syndrome	0.000193	0.00721	CbGeAlD
Propranolol—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000193	0.00111	CcSEcCtD
Propranolol—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000192	0.00111	CcSEcCtD
Propranolol—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000192	0.00111	CcSEcCtD
Propranolol—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000192	0.00111	CcSEcCtD
Propranolol—Rash—Stavudine—acquired immunodeficiency syndrome	0.000192	0.00111	CcSEcCtD
Propranolol—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000192	0.00111	CcSEcCtD
Propranolol—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000192	0.00111	CcSEcCtD
Propranolol—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000191	0.0011	CcSEcCtD
Propranolol—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.00019	0.0011	CcSEcCtD
Propranolol—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00019	0.0011	CcSEcCtD
Propranolol—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.00019	0.0011	CcSEcCtD
Propranolol—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00019	0.0011	CcSEcCtD
Propranolol—Rash—Abacavir—acquired immunodeficiency syndrome	0.000189	0.00109	CcSEcCtD
Propranolol—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000189	0.00109	CcSEcCtD
Propranolol—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000189	0.00109	CcSEcCtD
Propranolol—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000188	0.00109	CcSEcCtD
Propranolol—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000187	0.00108	CcSEcCtD
Propranolol—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000186	0.00697	CbGeAlD
Propranolol—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000186	0.00108	CcSEcCtD
Propranolol—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000185	0.00107	CcSEcCtD
Propranolol—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000185	0.00693	CbGeAlD
Propranolol—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000185	0.00107	CcSEcCtD
Propranolol—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000185	0.00107	CcSEcCtD
Propranolol—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000184	0.00106	CcSEcCtD
Propranolol—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000184	0.00106	CcSEcCtD
Propranolol—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000183	0.00106	CcSEcCtD
Propranolol—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.00106	CcSEcCtD
Propranolol—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.00106	CcSEcCtD
Propranolol—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000182	0.00682	CbGeAlD
Propranolol—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000182	0.00105	CcSEcCtD
Propranolol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000181	0.00105	CcSEcCtD
Propranolol—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000181	0.00105	CcSEcCtD
Propranolol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000181	0.00105	CcSEcCtD
Propranolol—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000181	0.00105	CcSEcCtD
Propranolol—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000181	0.00105	CcSEcCtD
Propranolol—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000179	0.00104	CcSEcCtD
Propranolol—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000179	0.00103	CcSEcCtD
Propranolol—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000178	0.00103	CcSEcCtD
Propranolol—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000178	0.00667	CbGeAlD
Propranolol—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000178	0.00103	CcSEcCtD
Propranolol—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000178	0.00103	CcSEcCtD
Propranolol—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000177	0.00103	CcSEcCtD
Propranolol—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000177	0.00102	CcSEcCtD
Propranolol—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000177	0.00102	CcSEcCtD
Propranolol—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000177	0.00102	CcSEcCtD
Propranolol—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000176	0.00102	CcSEcCtD
Propranolol—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000176	0.00102	CcSEcCtD
Propranolol—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000176	0.00102	CcSEcCtD
Propranolol—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000176	0.00102	CcSEcCtD
Propranolol—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000176	0.00102	CcSEcCtD
Propranolol—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000175	0.00656	CbGeAlD
Propranolol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000175	0.00101	CcSEcCtD
Propranolol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000174	0.00101	CcSEcCtD
Propranolol—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000172	0.000995	CcSEcCtD
Propranolol—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000171	0.00642	CbGeAlD
Propranolol—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000171	0.000991	CcSEcCtD
Propranolol—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000171	0.000989	CcSEcCtD
Propranolol—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000171	0.000988	CcSEcCtD
Propranolol—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000171	0.000987	CcSEcCtD
Propranolol—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.00017	0.000981	CcSEcCtD
Propranolol—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000169	0.000979	CcSEcCtD
Propranolol—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000169	0.000979	CcSEcCtD
Propranolol—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000169	0.00634	CbGeAlD
Propranolol—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.000974	CcSEcCtD
Propranolol—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000168	0.000974	CcSEcCtD
Propranolol—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000168	0.000973	CcSEcCtD
Propranolol—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000168	0.000973	CcSEcCtD
Propranolol—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.000971	CcSEcCtD
Propranolol—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000167	0.000965	CcSEcCtD
Propranolol—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000167	0.000965	CcSEcCtD
Propranolol—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000167	0.000964	CcSEcCtD
Propranolol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000166	0.000962	CcSEcCtD
Propranolol—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000164	0.00095	CcSEcCtD
Propranolol—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000164	0.000948	CcSEcCtD
Propranolol—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000163	0.000945	CcSEcCtD
Propranolol—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000163	0.000943	CcSEcCtD
Propranolol—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000163	0.000942	CcSEcCtD
Propranolol—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000163	0.000941	CcSEcCtD
Propranolol—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000163	0.00094	CcSEcCtD
Propranolol—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000163	0.00094	CcSEcCtD
Propranolol—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000162	0.000936	CcSEcCtD
Propranolol—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000162	0.000934	CcSEcCtD
Propranolol—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000162	0.000934	CcSEcCtD
Propranolol—ABCB1—blood—acquired immunodeficiency syndrome	0.000161	0.00604	CbGeAlD
Propranolol—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00016	0.000923	CcSEcCtD
Propranolol—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000159	0.00092	CcSEcCtD
Propranolol—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000157	0.00091	CcSEcCtD
Propranolol—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000157	0.000909	CcSEcCtD
Propranolol—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000157	0.000905	CcSEcCtD
Propranolol—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000157	0.000905	CcSEcCtD
Propranolol—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000156	0.000905	CcSEcCtD
Propranolol—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000156	0.00584	CbGeAlD
Propranolol—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000155	0.00582	CbGeAlD
Propranolol—Rash—Indinavir—acquired immunodeficiency syndrome	0.000155	0.000897	CcSEcCtD
Propranolol—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000155	0.000896	CcSEcCtD
Propranolol—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000154	0.000893	CcSEcCtD
Propranolol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000154	0.000889	CcSEcCtD
Propranolol—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000152	0.00088	CcSEcCtD
Propranolol—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000152	0.000876	CcSEcCtD
Propranolol—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.00015	0.000868	CcSEcCtD
Propranolol—ABCB1—vagina—acquired immunodeficiency syndrome	0.00015	0.0056	CbGeAlD
Propranolol—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000149	0.000864	CcSEcCtD
Propranolol—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000149	0.000864	CcSEcCtD
Propranolol—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000148	0.000855	CcSEcCtD
Propranolol—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000148	0.000854	CcSEcCtD
Propranolol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000147	0.000851	CcSEcCtD
Propranolol—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000147	0.000848	CcSEcCtD
Propranolol—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000146	0.000847	CcSEcCtD
Propranolol—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000146	0.000845	CcSEcCtD
Propranolol—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000146	0.000844	CcSEcCtD
Propranolol—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000142	0.000822	CcSEcCtD
Propranolol—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000141	0.000818	CcSEcCtD
Propranolol—ABCB1—lung—acquired immunodeficiency syndrome	0.000141	0.00529	CbGeAlD
Propranolol—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000141	0.000814	CcSEcCtD
Propranolol—Rash—Delavirdine—acquired immunodeficiency syndrome	0.00014	0.000811	CcSEcCtD
Propranolol—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.00014	0.00081	CcSEcCtD
Propranolol—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000139	0.000805	CcSEcCtD
Propranolol—CYP2D6—brain—acquired immunodeficiency syndrome	0.000139	0.00521	CbGeAlD
Propranolol—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000138	0.000799	CcSEcCtD
Propranolol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000136	0.000787	CcSEcCtD
Propranolol—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000136	0.000784	CcSEcCtD
Propranolol—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000135	0.000783	CcSEcCtD
Propranolol—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000132	0.000764	CcSEcCtD
Propranolol—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000131	0.0049	CbGeAlD
Propranolol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000131	0.000757	CcSEcCtD
Propranolol—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000131	0.000756	CcSEcCtD
Propranolol—Rash—Ritonavir—acquired immunodeficiency syndrome	0.00013	0.00075	CcSEcCtD
Propranolol—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.00013	0.000749	CcSEcCtD
Propranolol—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000129	0.000747	CcSEcCtD
Propranolol—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000126	0.00472	CbGeAlD
Propranolol—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000126	0.000728	CcSEcCtD
Propranolol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000125	0.000722	CcSEcCtD
Propranolol—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000125	0.000722	CcSEcCtD
Propranolol—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000125	0.000721	CcSEcCtD
Propranolol—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000122	0.000707	CcSEcCtD
Propranolol—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.00012	0.000695	CcSEcCtD
Propranolol—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000119	0.000689	CcSEcCtD
Propranolol—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000119	0.000688	CcSEcCtD
Propranolol—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000118	0.00068	CcSEcCtD
Propranolol—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.000649	CcSEcCtD
Propranolol—ABCB1—brain—acquired immunodeficiency syndrome	0.0001	0.00375	CbGeAlD
Propranolol—ABCB1—lymph node—acquired immunodeficiency syndrome	9.67e-05	0.00362	CbGeAlD
Propranolol—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	1.76e-06	0.00417	CbGpPWpGaD
Propranolol—HTR1B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	1.71e-06	0.00404	CbGpPWpGaD
Propranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	1.68e-06	0.00397	CbGpPWpGaD
Propranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	1.64e-06	0.00388	CbGpPWpGaD
Propranolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	1.6e-06	0.0038	CbGpPWpGaD
Propranolol—HTR1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.6e-06	0.0038	CbGpPWpGaD
Propranolol—HTR1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.58e-06	0.00375	CbGpPWpGaD
Propranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	1.58e-06	0.00373	CbGpPWpGaD
Propranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	1.58e-06	0.00373	CbGpPWpGaD
Propranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	1.54e-06	0.00365	CbGpPWpGaD
Propranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	1.54e-06	0.00365	CbGpPWpGaD
Propranolol—ADRB3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.54e-06	0.00364	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.51e-06	0.00359	CbGpPWpGaD
Propranolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	1.51e-06	0.00357	CbGpPWpGaD
Propranolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	1.51e-06	0.00357	CbGpPWpGaD
Propranolol—HTR1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.51e-06	0.00357	CbGpPWpGaD
Propranolol—HTR1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.51e-06	0.00357	CbGpPWpGaD
Propranolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.51e-06	0.00357	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.47e-06	0.00349	CbGpPWpGaD
Propranolol—HTR1A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	1.44e-06	0.00342	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.44e-06	0.0034	CbGpPWpGaD
Propranolol—ADRB1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	1.41e-06	0.00334	CbGpPWpGaD
Propranolol—ADRB3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.39e-06	0.00328	CbGpPWpGaD
Propranolol—ADRB2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	1.38e-06	0.00327	CbGpPWpGaD
Propranolol—CYP1A1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	1.37e-06	0.00325	CbGpPWpGaD
Propranolol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	1.37e-06	0.00325	CbGpPWpGaD
Propranolol—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.36e-06	0.00321	CbGpPWpGaD
Propranolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	1.35e-06	0.0032	CbGpPWpGaD
Propranolol—HTR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	1.35e-06	0.0032	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.33e-06	0.00315	CbGpPWpGaD
Propranolol—HTR1A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	1.3e-06	0.00308	CbGpPWpGaD
Propranolol—ADRB1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.28e-06	0.00302	CbGpPWpGaD
Propranolol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.26e-06	0.00299	CbGpPWpGaD
Propranolol—ADRB2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.25e-06	0.00296	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.24e-06	0.00293	CbGpPWpGaD
Propranolol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.23e-06	0.00292	CbGpPWpGaD
Propranolol—HTR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	1.22e-06	0.00289	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.22e-06	0.00289	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.22e-06	0.00288	CbGpPWpGaD
Propranolol—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	1.21e-06	0.00286	CbGpPWpGaD
Propranolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	1.2e-06	0.00284	CbGpPWpGaD
Propranolol—ADRB1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.2e-06	0.00284	CbGpPWpGaD
Propranolol—ADRB1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.2e-06	0.00284	CbGpPWpGaD
Propranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.2e-06	0.00284	CbGpPWpGaD
Propranolol—ADRB2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.17e-06	0.00278	CbGpPWpGaD
Propranolol—ADRB2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.17e-06	0.00278	CbGpPWpGaD
Propranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.17e-06	0.00278	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.17e-06	0.00278	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.17e-06	0.00276	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.17e-06	0.00276	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—TAT—acquired immunodeficiency syndrome	1.16e-06	0.00275	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.16e-06	0.00275	CbGpPWpGaD
Propranolol—HTR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	1.15e-06	0.00272	CbGpPWpGaD
Propranolol—HTR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	1.15e-06	0.00272	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.15e-06	0.00272	CbGpPWpGaD
Propranolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	1.15e-06	0.00272	CbGpPWpGaD
Propranolol—HTR1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.15e-06	0.00272	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.14e-06	0.00271	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.14e-06	0.00271	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.14e-06	0.00271	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.12e-06	0.00266	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.12e-06	0.00265	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.1e-06	0.00261	CbGpPWpGaD
Propranolol—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	1.1e-06	0.0026	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.09e-06	0.00259	CbGpPWpGaD
Propranolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.08e-06	0.00256	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.06e-06	0.00251	CbGpPWpGaD
Propranolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.06e-06	0.0025	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.06e-06	0.0025	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.04e-06	0.00246	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.04e-06	0.00246	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.04e-06	0.00246	CbGpPWpGaD
Propranolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	1.03e-06	0.00245	CbGpPWpGaD
Propranolol—HTR1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.03e-06	0.00245	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.01e-06	0.0024	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—AGPS—acquired immunodeficiency syndrome	9.87e-07	0.00234	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—AGPS—acquired immunodeficiency syndrome	9.86e-07	0.00234	CbGpPWpGaD
Propranolol—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	9.76e-07	0.00231	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	9.65e-07	0.00229	CbGpPWpGaD
Propranolol—ADRB1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	9.13e-07	0.00216	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.09e-07	0.00215	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.06e-07	0.00215	CbGpPWpGaD
Propranolol—ADRB2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	8.93e-07	0.00212	CbGpPWpGaD
Propranolol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	8.75e-07	0.00207	CbGpPWpGaD
Propranolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	8.75e-07	0.00207	CbGpPWpGaD
Propranolol—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	8.73e-07	0.00207	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.7e-07	0.00206	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.7e-07	0.00206	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	8.69e-07	0.00206	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	8.56e-07	0.00203	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.52e-07	0.00202	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.52e-07	0.00202	CbGpPWpGaD
Propranolol—SLC22A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	8.5e-07	0.00201	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	8.39e-07	0.00199	CbGpPWpGaD
Propranolol—ADRB1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	8.23e-07	0.00195	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.22e-07	0.00195	CbGpPWpGaD
Propranolol—ADRB2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	8.05e-07	0.00191	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—TAT—acquired immunodeficiency syndrome	7.93e-07	0.00188	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	7.89e-07	0.00187	CbGpPWpGaD
Propranolol—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	7.87e-07	0.00186	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.86e-07	0.00186	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	7.83e-07	0.00185	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	7.78e-07	0.00184	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.73e-07	0.00183	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.73e-07	0.00183	CbGpPWpGaD
Propranolol—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	7.59e-07	0.0018	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.24e-07	0.00172	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.21e-07	0.00171	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.21e-07	0.00171	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	7.14e-07	0.00169	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.11e-07	0.00168	CbGpPWpGaD
Propranolol—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	7.11e-07	0.00168	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.09e-07	0.00168	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.06e-07	0.00167	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	6.93e-07	0.00164	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.93e-07	0.00164	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.93e-07	0.00164	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	6.9e-07	0.00163	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.78e-07	0.00161	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.78e-07	0.00161	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.77e-07	0.0016	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.77e-07	0.0016	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	6.74e-07	0.0016	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.63e-07	0.00157	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.63e-07	0.00157	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.62e-07	0.00157	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.62e-07	0.00157	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.55e-07	0.00155	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.52e-07	0.00154	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	6.49e-07	0.00154	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.49e-07	0.00154	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.49e-07	0.00154	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.48e-07	0.00153	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.41e-07	0.00152	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.38e-07	0.00151	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	6.33e-07	0.0015	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.27e-07	0.00148	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.26e-07	0.00148	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.16e-07	0.00146	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.16e-07	0.00146	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.13e-07	0.00145	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.13e-07	0.00145	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.13e-07	0.00145	CbGpPWpGaD
Propranolol—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	6.12e-07	0.00145	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.02e-07	0.00143	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.02e-07	0.00143	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.99e-07	0.00142	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	5.97e-07	0.00141	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.89e-07	0.0014	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.89e-07	0.0014	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.88e-07	0.00139	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.84e-07	0.00138	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.79e-07	0.00137	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	5.52e-07	0.00131	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	5.39e-07	0.00128	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.37e-07	0.00127	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.3e-07	0.00126	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.16e-07	0.00122	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.08e-07	0.0012	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	5.08e-07	0.0012	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	5.06e-07	0.0012	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.05e-07	0.0012	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.97e-07	0.00118	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.94e-07	0.00117	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.86e-07	0.00115	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.86e-07	0.00115	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.69e-07	0.00111	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.66e-07	0.0011	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.65e-07	0.0011	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.62e-07	0.00109	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.59e-07	0.00109	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.58e-07	0.00109	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.57e-07	0.00108	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.57e-07	0.00108	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.55e-07	0.00108	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.52e-07	0.00107	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.51e-07	0.00107	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.48e-07	0.00106	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.45e-07	0.00105	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.41e-07	0.00105	CbGpPWpGaD
Propranolol—SLC22A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.32e-07	0.00102	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	4.3e-07	0.00102	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.28e-07	0.00101	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.22e-07	0.001	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.2e-07	0.000995	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.19e-07	0.000991	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.13e-07	0.000978	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.11e-07	0.000973	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.09e-07	0.000969	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.04e-07	0.000956	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	3.9e-07	0.000924	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.87e-07	0.000917	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.79e-07	0.000897	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.7e-07	0.000877	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.64e-07	0.000862	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.64e-07	0.000862	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.56e-07	0.000843	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.56e-07	0.000843	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	3.51e-07	0.000831	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.48e-07	0.000824	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.48e-07	0.000824	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.48e-07	0.000823	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.42e-07	0.000811	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.37e-07	0.000799	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.32e-07	0.000786	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.13e-07	0.000742	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	3.11e-07	0.000736	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.06e-07	0.000725	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.77e-07	0.000656	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.73e-07	0.000646	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.71e-07	0.000641	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.69e-07	0.000636	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.67e-07	0.000632	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.65e-07	0.000627	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.63e-07	0.000622	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.61e-07	0.000618	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.57e-07	0.000608	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.54e-07	0.000602	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.49e-07	0.000591	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.44e-07	0.000578	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.44e-07	0.000578	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.43e-07	0.000575	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.42e-07	0.000572	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.39e-07	0.000565	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.39e-07	0.000565	CbGpPWpGaD
Propranolol—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.36e-07	0.000559	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.33e-07	0.000553	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	2.03e-07	0.00048	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—ALB—acquired immunodeficiency syndrome	2.02e-07	0.000479	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.98e-07	0.000469	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.81e-07	0.000428	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.8e-07	0.000426	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	1.46e-07	0.000347	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.44e-07	0.000341	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.43e-07	0.00034	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.43e-07	0.000338	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.41e-07	0.000334	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.4e-07	0.000332	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	1.38e-07	0.000328	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.38e-07	0.000326	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.37e-07	0.000325	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	1.13e-07	0.000268	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.1e-07	0.000262	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.06e-07	0.000252	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.04e-07	0.000247	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	8.82e-08	0.000209	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.47e-08	0.000201	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.28e-08	0.000196	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.1e-08	0.000192	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	6.81e-08	0.000161	CbGpPWpGaD
